AbbVie’s newer immunology drugs are offsetting Humira’s decline, sending stock up 5%
AbbVie’s earnings topped estimates, and it offered an upbeat view of 2025. Source link
AbbVie’s newer immunology drugs are offsetting Humira’s decline, sending stock up 5% Read More »